Cell-surface receptors guide antisense therapy to mutant KRAS in pancreatic cancer cells

AI Summary

Researchers at Cancer Research UK Scotland Institute and University of Glasgow identified a pathway that allows antisense oligonucleotides (ASOs) to enter pancreatic cancer cells, providing new methods to improve antisense therapy effectiveness. The study offers potential therapeutic advances for shutting down mutant KRAS proteins in cancer treatment.

Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer. In a study published in the Journal of Cell Biology (JCB), researchers at the Cancer Research UK Scotland Institute and the University of Glasgow identify a pathway by which ASOs enter cells and reach their targets, suggesting new ways to enhance the effectiveness of antisense therapy.